Skip to main content
S 1038 118th Congress Senate Health Business records Congressional oversight Government information and archives Health care costs and insurance Home and outpatient care Inflation and prices Medicaid Prescription drugs Public contracts and procurement Retail and wholesale trades State and local government operations User charges and fees

Drug Price Transparency in Medicaid Act of 2023

Introduced: March 29, 2023 Introduced by: Welch, Peter Democratic · Vermont See on congress.gov
Sign in to write a letter Sign in to watch
This bill died when the 118th Congress ended
It never became law before the 118th Congress (2023–2024) adjourned, and bills don't carry over to the next Congress. It would have to be reintroduced. You can still save it for reference, but it won't receive updates.
 Everywhere this bill has been 2 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Mar 29, 2023
Read twice and referred to the Committee on Finance.
Mar 29, 2023
Introduced in Senate
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

 Plain-English summary Congressional Research Service

Drug Price Transparency in Medicaid Act of 2023

This bill requires pass-through pricing models, and prohibits spread-pricing, for payment arrangements with pharmacy benefit managers under Medicaid. The bill also extends funding for retail pharmacy surveys and requires additional information with respect to price concessions and survey participation to be made publicly available.

What's happening now March 29, 2023

Read twice and referred to the Committee on Finance.

 Related & companion bills 2
  • HR 3561 Related bill PATIENT Act of 2023
  • HR 1613 Identical bill Drug Price Transparency in Medicaid Act of 2023
 Bill text 1 version

Source documents hosted by congress.gov.

 Committees of jurisdiction 1
 Lobbying activity 9

Registered lobbyists who named this bill in their disclosure filings. Source: federal Lobbying Disclosure Act filings.

  • THE KROGER CO.
    for KROGER CO · Ohio · 1st Quarter (Jan 1 - Mar 31) 2026
  • THE KROGER CO.
    for KROGER CO · Ohio · 4th Quarter (Oct 1 - Dec 31) 2025
  • THE KROGER CO.
    for KROGER CO · Ohio · 3rd Quarter (July 1 - Sep 30) 2025
  • BANNER PUBLIC AFFAIRS, LLC
    for THE CIGNA GROUP AND SUBSIDIARIES (FKA CIGNA CORPORATION AND SUBSIDIARIES) · District of Columbia · 2nd Quarter (Apr 1 - June 30) 2025
  • THE KROGER CO.
    for KROGER CO · Ohio · 2nd Quarter (Apr 1 - June 30) 2025
  • NATIONAL TAXPAYERS UNION
    for NATIONAL TAXPAYERS UNION · District of Columbia · 2nd Quarter (Apr 1 - June 30) 2025
See all 9 filings →
 Cosponsors 3
All 3 Democratic 1 Republican 2
D
Gillibrand, Kirsten E.
New York · Apr 30, 2024
 R
Capito, Shelley Moore
West Virginia · May 3, 2023
 R
Marshall, Roger
Kansas · Mar 29, 2023
Cite this page click to expand
APA
U.S. Congress. (2026). S. 1038: Drug Price Transparency in Medicaid Act of 2023. 118th Congress. Open America. https://openamerica.io/bill/118-S-1038/
MLA
"S. 1038: Drug Price Transparency in Medicaid Act of 2023." 118th Congress, 2026, Open America, https://openamerica.io/bill/118-S-1038/.
Bluebook (legal)
S. 1038, 118th Cong. (2026), https://openamerica.io/bill/118-S-1038/.
Markdown link
[S. 1038: Drug Price Transparency in Medicaid Act of 2023](https://openamerica.io/bill/118-S-1038/)
Report a problem